Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17209394 | 0.89 | IRAK4 (0.54) | IRAK4HRH3HRH1KCNH2L3MBTL1 | |
| SCHEMBL17209395 | 0.89 | IRAK4 (0.72) | IRAK4HRH3HRH1 | |
| SCHEMBL21026294 | 0.81 | IRAK4 (0.62) | IRAK4 | |
| SCHEMBL23707456 | 0.76 | HRH1 (0.47) | IRAK4HRH1L3MBTL1LMNAJAK3 | |
| SCHEMBL17209402 | 0.75 | IRAK4 (0.65) | IRAK4CCR4 | |
| SCHEMBL17209398 | 0.75 | HRH1 (0.51) | IRAK4HRH3HRH1L3MBTL1LMNA | |
| Hydrochloric Acid SCHEMBL2797523 | 0.75 | JAK3 (0.48) | HRH1L3MBTL1LMNAHTTSMN1; SMN2 | |
| SCHEMBL8482286 | 0.75 | L3MBTL1 (0.46) | IRAK4L3MBTL1LMNAJAK3CYP2C19 | |
| SCHEMBL8482284 | 0.75 | L3MBTL1 (0.46) | IRAK4L3MBTL1LMNAJAK3CYP2C19 | |
| SCHEMBL8487583 | 0.74 | L3MBTL1 (0.44) | IRAK4L3MBTL1LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150329498-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20150329498-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2015-11-19 | — | — | US | disclosed |
| WO-2015164374-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329498-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885HRH3 2036/4885HRH1 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.